Table 1.
Background of patients
| All n = 178 | Control group n = 56 | Novel ARATs group n = 122 | P value | |
|---|---|---|---|---|
| Age, years | 76 (72–81) | 76 (73–79) | 77 (72–82) | 0.807 |
| iPSA, ng/mL | 26 (11–100) | 29 (12–97) | 24 (10–100) | 0.819 |
| Biopsy Gleason score | 0.580 | |||
| ≤7 | 40 (22%) | 10 (18%) | 30 (25%) | |
| 8 | 29 (16%) | 9 (16%) | 20 (16%) | |
| ≥9 | 109 (61%) | 37 (66%) | 72 (59%) | |
| Clinical stage | ||||
| cT4 or cN1 | 68 (38%) | 22 (39%) | 46 (38%) | 0.840 |
| History of radical treatment | 0.378 | |||
| None | 79 (44%) | 29 (52%) | 50 (41%) | |
| Prostatectomy | 58 (33%) | 15 (27%) | 43 (35%) | |
| Radiation therapy | 41 (23%) | 12 (21%) | 29 (24%) | |
| PSADT, months | 3.5 (2.0–6.1) | 4.2 (2.2–6.4) | 3.2 (1.8–5.9) | 0.274 |
| Follow-up period, months | 37 (20–58 | 47 (29–74) | 35 (18–54) |
All data are presented as n (%) or medians (interquartile ranges). ARATs, androgen receptor axis-targeted agents; iPSA, initial prostate-specific antigen; PSADT, prostate-specific antigen doubling time.